A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer

ClinicalTrials.gov ID: NCT00584012

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00584012. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This purpose of this study is to evaluate the use of two medications, docetaxel and lovastatin to determine the highest dose of lovastatin and docetaxel that can be given safely as well as the safety of combining the two drugs and the effect on the subject's tumor. Subjects can have any cancer.

Study identification

NCT ID: NCT00584012
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Susan L Roeder; Other
Enrollment: 9 participants

Conditions and interventions

Conditions

Interventions

Lovastatin Drug
Docetaxel Drug

Drug

Eligibility (public fields only)

Age range: 19 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2004 (Actual)
Primary completion: Apr 2009 (Actual)
Completion: Apr 2009 (Actual)
Last update posted: Oct 19, 2018

2004 – 2009

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Holden Comprehensive Cancer Center	Iowa City	Iowa	52242	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00584012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 19, 2018 · Synced Nov 15, 2026